Taxanes

Phase 3Small molecule

HHebei Medical University Fourth Hospital

Taxanes is one of 59 small molecule programs targeting Triple-Negative Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Triple-Negative Breast CancerActive, not recruiting

Breast CancerActive, not recruiting

Triple-Negative Breast CancerPhase 3

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Taxanes

HHebei Medical University Fourth Hospital

Phase 3

4 2

Megace

Bristol-Myers Squibb

Preclinical

4 3

DATROWAY

Daiichi Sankyo

Preclinical

4 4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 5

Spravato

WWim Janssens

Preclinical

2 6

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 7

Aquasol E

NNational Eye Institute (NEI)

Preclinical

—8

Dextromethorphan Hydrobromide

Boehringer Ingelheim

Preclinical

1 9

Perflutren Lipid Microcpheres

TThomas Jefferson University

Preclinical

2 10

Ablavar

LLantheus Medical Imaging

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2/3Active, not recruiting

Breast Cancer

NCT04290793

Q2 2027

Post-ApprovalRecruiting

Breast Cancer

NCT06217185

Q1 2030

Phase 3Active, not recruiting

Triple-Negative Breast Cancer

NCT02455141

Clinical

Trials by Indication[1]

Breast Cancer4 trials

TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT04760431·120 enrolled

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

Active, not recruiting·UUNICANCER·Phase 2·NCT02299999·1,460 enrolled

The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).

Recruiting·HHebei Medical University Fourth Hospital·Phase 4·NCT06217185·100 enrolled

Show 1 more trial

Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer

Active, not recruiting·HHebei Medical University Fourth Hospital·Phase 2/3·NCT04290793·113 enrolled

Triple-Negative Breast Cancer1 trial

Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer

Active, not recruiting·SShanghai Jiao Tong University School of Medicine·Phase 3·NCT02455141·786 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Taxanes. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Taxanes compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Taxanes. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hebei Medical University Fourth Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: HHebei Medical University Fourth Hospital

Taxanes

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q1 2030

Trials by Indication[1]

Breast Cancer4 trials

Triple-Negative Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News